Stevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of "Moderate Buy" by Analysts

Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company.

STVN has been the topic of several research analyst reports. Bank of America upped their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Wolfe Research assumed coverage on Stevanato Group in a research note on Friday, December 13th. They issued an "outperform" rating and a $28.00 target price on the stock. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd.

Institutional Investors Weigh In On Stevanato Group

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in shares of Stevanato Group by 4.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company's stock valued at $53,872,000 after purchasing an additional 115,050 shares during the last quarter. Glenmede Trust Co. NA grew its position in Stevanato Group by 12.7% during the third quarter. Glenmede Trust Co. NA now owns 35,941 shares of the company's stock valued at $719,000 after acquiring an additional 4,050 shares during the last quarter. AMI Asset Management Corp bought a new position in Stevanato Group during the fourth quarter valued at approximately $1,089,000. Raymond James & Associates raised its stake in shares of Stevanato Group by 21.8% during the third quarter. Raymond James & Associates now owns 281,455 shares of the company's stock worth $5,629,000 after acquiring an additional 50,380 shares in the last quarter. Finally, Natixis Advisors LLC lifted its holdings in shares of Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock worth $1,027,000 after acquiring an additional 8,669 shares during the last quarter.

Stevanato Group Price Performance

NYSE STVN traded up €0.29 ($0.30) during trading hours on Friday, hitting €22.47 ($23.16). The company had a trading volume of 287,500 shares, compared to its average volume of 357,291. The firm has a 50 day simple moving average of €21.82 and a 200 day simple moving average of €20.51. Stevanato Group has a 52 week low of €16.56 ($17.07) and a 52 week high of €34.73 ($35.80). The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of 47.81, a PEG ratio of 7.76 and a beta of 0.56. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) EPS for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €277.90 million for the quarter, compared to analysts' expectations of €274.36 million. During the same period in the prior year, the firm posted $0.16 EPS. Stevanato Group's revenue was up 2.4% on a year-over-year basis. Equities research analysts expect that Stevanato Group will post 0.5 earnings per share for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.